Compare Abbott Laboratories (ABT) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Cognizant Technology Solutions Corp — how do they compare? Abbott Laboratories trades at $109.06 (market cap $187.95B), while Cognizant Technology Solutions Corp trades at $57.32 (market cap $26.40B). The key difference: Abbott Laboratories is far larger — about 7.1× Cognizant Technology Solutions Corp's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | CTSH | |
|---|---|---|
Market Cap | $187.95B | $26.40B |
Sector | Health | Technology |
52-Week High | $136.62 | $86.70 |
52-Week Low | $82.57 | $38.73 |
Enterprise Value | $214.96B | $27.44B |
Dividend Yield | 2.32% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
CTSH trades at $58.31, up 1.11% today, near its consensus price target of $59.92. The stock shows bullish technical signals with moving averages supporting an uptrend, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed estimates, but revenue beat expectations, and the company maintains strong profitability with a net margin of 10.26%. AI initiatives and financial services growth are key drivers, as highlighted in recent earnings calls (Seeking Alpha, 2026-07-29).
Outlook: CTSH offers value with a P/E of 12.58 and stable cash flows, but faces risks from client spending caution and competitive pressures. Upside potential exists if AI investments yield growth, though macroeconomic headwinds could limit near-term gains. Analysts are mixed, with 43% recommending buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
